Peptides and NAFLD/MASLD: How GLP-1 and Tesamorelin Are Being Studied for Liver Fat Reduction

If you have fatty liver disease — officially called NAFLD or its updated name, MASLD — you may be wondering whether peptide therapies can actually move the needle on your liver health. The short answer: yes, and the evidence is now substantial enough that two drugs have reached FDA approval for this exact problem.

Peptides NAFLD MASLD research has accelerated dramatically over the last five years. Two peptide-based agents — GLP-1 receptor agonists (particularly semaglutide) and tesamorelin — are at the centre of this shift. One has now received FDA approval specifically for MASH. The other has shown striking liver fat reductions in clinical trials. This article breaks down how each works, what the data actually shows, and what it means for you.

What Is NAFLD/MASLD — and Why Does It Matter to Metabolic Patients?

NAFLD and MASLD refer to the same underlying condition: excess fat accumulation in liver cells that is not caused by alcohol. In 2023, leading liver disease societies formally renamed NAFLD to MASLD — Metabolic Dysfunction-Associated Steatotic Liver Disease — to better reflect what actually drives it.

That driver is metabolic dysfunction. Specifically:

• Insulin resistance
• Obesity and visceral (belly) fat
• Type 2 diabetes or prediabetes
• High triglycerides or low HDL cholesterol
• Hypertension

MASLD is now the most common chronic liver disease in the world. Estimates suggest it affects nearly one-third of the global adult population, with prevalence projected to exceed 55% of adults by 2040.

For metabolic syndrome patients, the numbers are even starker. Research shows that metabolic comorbidities are almost universally present in NAFLD: obesity in 51%, type 2 diabetes in 22.5%, dyslipidaemia in 69%, and metabolic syndrome in 42.5%.

The disease spectrum matters. MASLD starts as simple steatosis — fat in the liver, no inflammation yet. Left unaddressed, it can progress to:

1. MASH (Metabolic Dysfunction-Associated Steatohepatitis) — fat plus inflammation and liver cell injury
2. Fibrosis — early scarring of the liver
3. Cirrhosis — advanced, potentially irreversible scarring
4. Hepatocellular carcinoma — liver cancer

MASLD is now the leading indication for liver transplant in women in the United States. Most patients have no symptoms in the early stages. That is what makes it dangerous.

The Insulin Resistance Connection

If you have metabolic syndrome, insulin resistance is the likely thread connecting your liver disease to everything else. Insulin resistance is a key factor in MASLD pathogenesis — it drives increased release of free fatty acids into the liver and promotes hepatic de novo lipogenesis, essentially telling the liver to manufacture more fat than it can export or burn.

Visceral fat makes this worse. Abdominal fat is metabolically active. It releases fatty acids directly into the portal circulation, flooding the liver with lipids. It also produces inflammatory cytokines — TNF-α and IL-6 — that worsen liver inflammation and accelerate fibrosis.

This is precisely where peptide therapies have found their mechanistic opening.

How GLP-1 Receptor Agonists Target Liver Fat in NAFLD/MASLD

GLP-1 receptor agonists reduce liver fat through multiple converging mechanisms — not just by causing weight loss.

GLP-1 (glucagon-like peptide-1) is a hormone naturally released by your gut after eating. It tells your pancreas to release insulin, suppresses glucagon (which raises blood sugar), slows gastric emptying, and reduces appetite. Synthetic GLP-1 receptor agonists mimic and extend these effects.

Their liver benefits work through at least four pathways:

1. Reduced visceral fat — less abdominal fat means less fatty acid delivery to the liver
2. Improved insulin sensitivity — less insulin resistance means less hepatic lipogenesis
3. Direct hepatic effects — GLP-1 receptors are present in liver cells; agonism appears to modulate lipid metabolism directly and reduce inflammatory signalling
4. Improved glycaemic control — lower blood sugar reduces the substrate available for fat synthesis in the liver

A 2025 meta-analysis of 13 phase 2 and phase 3 randomised controlled trials involving 1,811 participants found that GLP-1 receptor agonists significantly reduced magnetic resonance-measured liver fat content, with a pooled mean reduction of 4.50% compared to placebo. That is a meaningful reduction in a patient population where even a 3–5% absolute reduction in liver fat fraction can have histological significance.

Semaglutide and GLP-1 Liver Steatosis Treatment: From Phase 2 to FDA Approval

Semaglutide is the most studied GLP-1 receptor agonist in MASLD — and now the most consequential.

The ESSENCE Trial. In November 2024, Novo Nordisk announced headline results from Part 1 of the Phase 3 ESSENCE trial. Semaglutide 2.4 mg once weekly was compared with placebo in approximately 800 adults with biopsy-proven MASH and stage 2 or 3 fibrosis. At 72 weeks:

• 62.9% of semaglutide patients achieved resolution of MASH without worsening of fibrosis, compared to approximately 34% on placebo
• Semaglutide demonstrated significant improvements in both MASH activity and liver fibrosis — an outcome that distinguished it from the Phase 2 results where fibrosis improvement was less clear

On August 15, 2025, the FDA granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) 2.4 mg for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis (F2–F3 fibrosis stages). This made it the first GLP-1 receptor agonist approved for this indication — and only the second drug ever approved specifically for MASH, after resmetirom in March 2024.

Part 2 of the ESSENCE trial continues through 240 weeks and will assess whether semaglutide reduces liver-related clinical events; results are expected in 2029.

Real-world comparative data is also emerging. A large-scale retrospective cohort study published in 2025 found that semaglutide was associated with 14% lower rates of composite adverse liver outcomes compared to other GLP-1 receptor agonists in patients with MASLD.

Key semaglutide data summary:

The 2025 AASLD Practice Guidance update confirmed that semaglutide showed a favourable hepatic safety profile in the ESSENCE trial, with no discontinuations due to liver enzyme elevations. The most common adverse events were gastrointestinal — nausea, diarrhoea, constipation, and vomiting — generally mild and transient.

Who is a candidate? The AASLD recommends patient selection based on MASH with stage 2–3 fibrosis, identified using non-invasive tests such as vibration-controlled transient elastography (VCTE 8–15 kPa), MR elastography (MRE 3.1–4.4 kPa), or enhanced liver fibrosis score (ELF 9.2–10.5). Liver biopsy is not required for most patients.

Semaglutide is not approved for patients with MASH cirrhosis. Those with compensated cirrhosis already on semaglutide for another indication should be monitored carefully.

If you are a metabolic patient with fatty liver and either obesity or type 2 diabetes, Meto's metabolic health programmes include physician-led evaluation that can assess your candidacy for GLP-1 therapy and monitor your liver and metabolic markers over time.

Tesamorelin NAFLD: How a Growth Hormone Peptide Targets Liver Fat

Tesamorelin operates through an entirely different axis — and its liver findings are among the most compelling in the peptide space, even if its regulatory pathway has taken a different course.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It does not administer growth hormone directly. Instead, it stimulates your pituitary gland to produce and secrete growth hormone in a natural, pulsatile pattern. Tesamorelin augments endogenous pulsatile growth hormone and downstream insulin-like growth factor-1 (IGF-1) secretion, and is FDA-approved to reduce visceral adiposity in HIV.

Growth hormone is a potent lipolytic hormone — it promotes the breakdown and mobilisation of fat, particularly visceral fat. By stimulating growth hormone production, tesamorelin also promotes an increase in IGF-1 levels, which further drives lipolysis — the breakdown of fats. This matters for the liver for the same reason visceral fat reduction matters with GLP-1: less visceral fat means less fatty acid overflow to the liver.

The Clinical Evidence on Tesamorelin and NAFLD

The landmark trial. A randomised, double-blind, multicentre trial conducted at Massachusetts General Hospital and the NIH's National Institute of Allergy and Infectious Diseases examined tesamorelin's effects on liver fat and histology in people living with HIV who had NAFLD.

After 12 months of treatment, liver fat in patients receiving tesamorelin had decreased by 32%, while liver fat in placebo patients increased by 5% from baseline — a 37% relative reduction in liver fat. Furthermore, 35% of patients in the tesamorelin group returned to liver fat values below 5%, compared to only 4% on placebo. These are striking numbers.

Using gene set enrichment analysis of paired liver biopsies, researchers found that tesamorelin increased hepatic expression of gene sets involved in oxidative phosphorylation and decreased expression of gene sets contributing to inflammation, tissue repair, and cell division. In plain terms: it shifted the liver toward burning fat more efficiently and turned down the inflammatory response.

Fibrosis protection. In the randomised controlled trial in HIV patients with NAFLD, tesamorelin reduced liver fat content and prevented liver inflammation and fibrosis progression.

Where we are now. Following the HIV trial results, a Phase II trial in non-HIV patients with NAFLD was initiated (NCT03375788). This prospective phase II trial with tesamorelin in non-HIV NAFLD patients represents the next critical step in establishing whether the findings generalise beyond the HIV population.

Key tesamorelin data summary:

Peptides NAFLD MASLD: Comparing GLP-1 and Tesamorelin Side by Side

Understanding the differences between these two approaches helps clarify who might benefit from each — and where they might eventually be used together.

The short version: Semaglutide now has the most robust evidence base and is the first choice for patients meeting the ESSENCE criteria. Tesamorelin showed remarkable liver fat reductions but its path to broader MASLD approval depends on the ongoing non-HIV Phase II trial data.

For metabolic syndrome patients, semaglutide's additional benefits — cardiovascular risk reduction, weight loss, glycaemic improvement — often make it the more logical first step when liver disease is present alongside obesity and type 2 diabetes.

What the Broader Peptide and MASLD Pipeline Looks Like

GLP-1 and GHRH are not the only peptide-based approaches under investigation for liver fat.

Tirzepatide (a dual GIP/GLP-1 agonist) showed positive Phase 2 results for MASH in the SYNERGY-NASH trial. It produces more pronounced weight loss than semaglutide and appears to have potent effects on liver fat.

Retatrutide (a triple GIP/GLP-1/glucagon agonist) has shown marked reductions in liver fat in early trials, making it one of the most-watched agents in the pipeline.

Resmetirom (a thyroid hormone receptor-β agonist) was the first agent approved for MASH in March 2024 and remains a non-GLP-1 alternative for patients who cannot tolerate GLP-1 therapy or do not have obesity.

The key insight for patients: this field has moved from having zero approved liver-specific therapies to having two within 18 months. The combination of GLP-1 agonism with visceral fat reduction — which is also what tesamorelin targets from a different axis — is at the centre of this progress.

What Metabolic Syndrome Patients Need to Understand

If you have metabolic syndrome and have been told you have a fatty liver, there are several things worth knowing right now.

1. Most patients are asymptomatic until fibrosis is advanced. Elevated liver enzymes (ALT, AST) can be a signal, but normal enzymes do not rule out significant steatosis or even MASH. Many patients discover moderate-to-advanced fibrosis only during imaging or evaluation for another condition.

2. Non-invasive testing is now the standard. Liver biopsy is not required to identify MASH with fibrosis. Vibration-controlled transient elastography (FibroScan), MR elastography, and validated blood panels (ELF score, FIB-4 index) can stratify your risk without an invasive procedure.

3. Metabolic co-management is essential. Peptide therapy does not replace optimising insulin resistance, blood pressure, lipids, and lifestyle. The patients who respond best to GLP-1 therapy for liver disease are those receiving comprehensive metabolic care — not just a weekly injection in isolation.

4. Semaglutide's approval is for MASH with fibrosis, not simple steatosis. If you have early-stage MASLD (steatosis without fibrosis), lifestyle intervention remains first-line. The pharmacological conversation becomes much more urgent at F2–F3 fibrosis.

5. Both GLP-1 and growth hormone axes matter. The tesamorelin data is a reminder that visceral fat is a metabolic organ, not just stored energy. Growth hormone signalling matters to liver health in ways that are mechanistically distinct from insulin sensitisation. Future combination protocols may leverage both.

Meto's Insulin Resistance & Prediabetes Reset and Prescription Weight Loss Programme are designed for exactly this level of complexity — integrating liver health, metabolic dysfunction, and personalised pharmacological management under physician oversight.

Conclusion

The science on peptides and NAFLD/MASLD has crossed from promising to clinically actionable. GLP-1 receptor agonists — particularly semaglutide — are now FDA-approved for MASH with fibrosis, supported by one of the clearest mechanistic and clinical evidence trails in metabolic medicine. Tesamorelin has demonstrated remarkable liver fat reduction in rigorous RCTs and is being studied in broader MASLD populations.

For metabolic syndrome patients with fatty liver disease, this is not a niche research topic. It is a direct clinical opportunity. The first step is getting a proper evaluation — one that looks at your liver, your insulin resistance, your visceral fat, and your full metabolic picture together.

Book a comprehensive liver and metabolic health assessment through Meto →

Meto connects you with physician specialists who understand the metabolic origins of fatty liver disease and can evaluate whether peptide therapy — GLP-1 or otherwise — is appropriate for your situation.

Frequently Asked Questions

Can peptides reduce liver fat in NAFLD/MASLD?

Yes. Both GLP-1 receptor agonists (like semaglutide) and tesamorelin have shown significant liver fat reductions in clinical trials. Semaglutide achieved MASH resolution in 62.9% of patients at 72 weeks in the ESSENCE trial, leading to FDA approval in August 2025. Tesamorelin reduced liver fat by 32% over 12 months in an RCT in HIV-positive NAFLD patients.

Is semaglutide approved for fatty liver disease?

Yes, as of August 15, 2025. Semaglutide (Wegovy) received FDA accelerated approval specifically for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis (F2–F3 fibrosis stages). This makes it the first and only GLP-1 receptor agonist approved for this indication. It is approved for use alongside a reduced-calorie diet and increased physical activity.

How does tesamorelin affect liver fat differently from GLP-1 therapies?

Tesamorelin works through the growth hormone axis rather than the incretin system. It stimulates the pituitary gland to release growth hormone in a natural pulsatile pattern, which elevates IGF-1 and promotes lipolysis — particularly visceral fat breakdown. This reduces the supply of fatty acids flooding the liver. GLP-1 receptor agonists work through insulin sensitisation, appetite suppression, direct hepatic receptor effects, and weight reduction. The mechanisms are complementary rather than redundant.

Do I need a liver biopsy to start treatment for MASLD/MASH?

No. Current AASLD guidance recommends using non-invasive tests to identify candidates for pharmacological therapy. These include vibration-controlled transient elastography (FibroScan), MR elastography, the enhanced liver fibrosis (ELF) score, and the FIB-4 index. Liver biopsy is impractical and unnecessary for most patients in clinical practice.

Who is not a good candidate for semaglutide as a MASH treatment?

Semaglutide is not approved for patients with MASH cirrhosis (end-stage fibrosis with portal hypertension). Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are also excluded. Those with a history of pancreatitis require careful individualised assessment. Patients with early MASLD (steatosis without significant fibrosis) do not currently have an approved pharmacological indication, though GLP-1 therapy may still be appropriate if they have obesity or type 2 diabetes.

Can a metabolic clinic like Meto help manage NAFLD/MASLD?

Yes. MASLD is fundamentally a metabolic disease. Effective management requires addressing insulin resistance, visceral fat, lipids, blood sugar, and blood pressure — not just liver enzymes in isolation. Meto's physician-led programmes integrate these dimensions, evaluate peptide therapy candidacy, and provide the ongoing monitoring that MASLD management requires. Start your assessment here.